These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 32327473)

  • 41. Recent Progress in Systemic Therapy for Advanced Hepatocellular Carcinoma.
    Sadagopan N; He AR
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279258
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Clinical research progression of molecular-targeted drugs and PD-1 inhibitors for advanced hepatocellular carcinoma].
    Lai JM; Hu S; Lin H; Luo H; Luo YB
    Zhonghua Zhong Liu Za Zhi; 2019 Jun; 41(6):406-409. PubMed ID: 31216824
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Medical oncology management of advanced hepatocellular carcinoma 2019: a reality check.
    Lee A; Lee FC
    Front Med; 2020 Jun; 14(3):273-283. PubMed ID: 31863306
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An update on atezolizumab for hepatocellular carcinoma.
    Ielasi L; Sansone V; Forgione A; Granito A; Benevento F; Tovoli F
    Drugs Today (Barc); 2021 Jun; 57(6):365-375. PubMed ID: 34151903
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prolonged response to Tyrosine Kinase Inhibitors followed by Immunotherapy in metastatic hepatocellular carcinoma: A rare case report.
    Roy P; Parthasarathy KM
    J Cancer Res Ther; 2023; 19(5):1457-1461. PubMed ID: 37787330
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Systemic therapy for advanced hepatocellular carcinoma: targeted therapies.
    Tella SH; Kommalapati A; Mahipal A
    Chin Clin Oncol; 2021 Feb; 10(1):10. PubMed ID: 32434345
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immune checkpoint inhibitors for hepatocellular carcinoma - A game changer in treatment landscape.
    Liu TH; Shen YC; Cheng AL
    J Formos Med Assoc; 2022 Aug; 121(8):1371-1383. PubMed ID: 35400583
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
    Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
    Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma.
    Brown ZJ; Yu SJ; Heinrich B; Ma C; Fu Q; Sandhu M; Agdashian D; Zhang Q; Korangy F; Greten TF
    Cancer Immunol Immunother; 2018 Aug; 67(8):1305-1315. PubMed ID: 29959458
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
    Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint.
    Chen J; Ji T; Zhao J; Li G; Zhang J; Jin R; Liu J; Liu X; Liang X; Huang D; Xie A; Lin H; Cang Y; Cai X
    Oncotarget; 2016 Jul; 7(27):41274-41284. PubMed ID: 27129180
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immuno-oncology for Hepatocellular Carcinoma: The Present and the Future.
    Armstrong SA; He AR
    Clin Liver Dis; 2020 Nov; 24(4):739-753. PubMed ID: 33012456
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Expanding the immunotherapy roadmap for hepatocellular carcinoma.
    Baretti M; Kim AK; Anders RA
    Cancer Cell; 2022 Mar; 40(3):252-254. PubMed ID: 35290785
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combinatorial immunotherapy of sorafenib and blockade of programmed death-ligand 1 induces effective natural killer cell responses against hepatocellular carcinoma.
    Wang Y; Li H; Liang Q; Liu B; Mei X; Ma Y
    Tumour Biol; 2015 Mar; 36(3):1561-6. PubMed ID: 25371070
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oral chemotherapy for the treatment of hepatocellular carcinoma.
    Yamamoto S; Kondo S
    Expert Opin Pharmacother; 2018 Jun; 19(9):993-1001. PubMed ID: 29913090
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Current and novel approaches in the pharmacological treatment of hepatocellular carcinoma.
    Villarruel-Melquiades F; Mendoza-Garrido ME; García-Cuellar CM; Sánchez-Pérez Y; Pérez-Carreón JI; Camacho J
    World J Gastroenterol; 2023 May; 29(17):2571-2599. PubMed ID: 37213397
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeted therapies for hepatocellular carcinoma.
    Skelton MR; O'Neil B
    Clin Adv Hematol Oncol; 2008 Mar; 6(3):209-18. PubMed ID: 18391920
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer.
    Bao MH; Wong CC
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359884
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cabozantinib: An evolving therapy for hepatocellular carcinoma.
    El-Khoueiry AB; Hanna DL; Llovet J; Kelley RK
    Cancer Treat Rev; 2021 Jul; 98():102221. PubMed ID: 34029957
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait.
    Rizzo A; Ricci AD; Brandi G
    Immunotherapy; 2021 Jun; 13(8):637-644. PubMed ID: 33820447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.